[Current Data] Rule running report - 2023-10-27 18:47:53.288638

Nr2MedPage Today) -- MADRID -- Immunotherapy, chemotherapy, and a PARP inhibitor in the first line improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, according to the… succesfully run! 0 Anläufe!